Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...

Medically reviewed by Robert Burakoff, MD Crohn's disease is an inflammatory bowel disease that occurs when inflammation in ...

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes episodic inflammation, swelling, and irritation within the digestive tract. There is no cure for Crohn’s disease but ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

2024 — A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in ...

Missing piece in Crohn’s disease is discovered—immune cells that vanish before symptoms even start! This groundbreaking ...

The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of R&D at Tr1X, with patients enrolling at leading stem cell transplant centers across ...

Studies show how some plant foods can reduce inflammation, prevent flare-ups and even lower surgery risks for those with ...

Crohn’s disease and ulcerative colitis are both inflammatory bowel diseases with similar symptoms. However, some key differences include the areas they affect, diagnostic tools, and treatment plans.

Ustekinumab treatment may have better persistence than anti-TNF therapy as a second-line therapy in patients with Crohn's disease, along with improvements seen in clinical remission rates.